Carfilzomib

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1722 publications

MRD-guided induction-intensification with daratumumab-carfilzomib-based regimen followed by ASCT in patients with newly diagnosed multiple myeloma.

MRD-guided induction-intensification with daratumumab-carfilzomib-based regimen followed by ASCT in patients with newly diagnosed multiple myeloma.

Journal: Leukemia & lymphoma
Published: September 06, 2026

Risk factors for carfilzomib-related cardiovascular adverse events in Chinese patients with multiple myeloma: A real-world retrospective cohort study.

Risk factors for carfilzomib-related cardiovascular adverse events in Chinese patients with multiple myeloma: A real-world retrospective cohort study.

Journal: The Journal of international medical research
Published: August 20, 2026

Tumor-selective Mcl1 degradation by AUTAC uncouples antitumor efficacy from cardiotoxicity.

Tumor-selective Mcl1 degradation by AUTAC uncouples antitumor efficacy from cardiotoxicity.

Journal: bioRxiv : the preprint server for biology
Published: July 03, 2026

Plain language summary of publication of how long people with relapsed multiple myeloma lived after treatment in the IKEMA study: Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone.

Plain language summary of publication of how long people with relapsed multiple myeloma lived after treatment in the IKEMA study: Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone.

Journal: Future oncology (London, England)
Published: June 27, 2026

Incidence and Associated Risk Factors in the Development of Carfilzomib-Induced Cardiovascular Toxicity.

Incidence and Associated Risk Factors in the Development of Carfilzomib-Induced Cardiovascular Toxicity.

Journal: Current oncology (Toronto, Ont.)
Published: June 22, 2026

A Bioequivalence Study Comparing Two Pomalidomide Hard Capsule Formulations in Healthy Chilean Subjects.

A Bioequivalence Study Comparing Two Pomalidomide Hard Capsule Formulations in Healthy Chilean Subjects.

Journal: Pharmaceuticals (Basel, Switzerland)
Published: June 02, 2026

Development and Validation of a Rapid LC-MS/MS Method for Carfilzomib Quantification in Plasma from Multiple Myeloma Patients.

Development and Validation of a Rapid LC-MS/MS Method for Carfilzomib Quantification in Plasma from Multiple Myeloma Patients.

Journal: Journal of visualized experiments : JoVE
Published: June 01, 2026

Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy.

Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy.

Journal: The New England journal of medicine
Published: May 29, 2026

A phenotype-to-mechanism framework links phenome-wide comorbidity architecture to molecular mechanisms and therapeutic discovery in complex diseases.

A phenotype-to-mechanism framework links phenome-wide comorbidity architecture to molecular mechanisms and therapeutic discovery in complex diseases.

Journal: medRxiv : the preprint server for health sciences
Published: May 25, 2026

Correction to 'Mucin 20 Modulates Proteasome Capacity Through c-Met Signalling to Increase Carfilzomib Sensitivity in Mantle Cell Lymphoma'.

Correction to 'Mucin 20 Modulates Proteasome Capacity Through c-Met Signalling to Increase Carfilzomib Sensitivity in Mantle Cell Lymphoma'.

Journal: Journal of cellular and molecular medicine
Published: May 19, 2026

Proteome profiling reveals NQO2 activity contributing to proteasome inhibitor resistance in multiple myeloma cell lines.

Proteome profiling reveals NQO2 activity contributing to proteasome inhibitor resistance in multiple myeloma cell lines.

Journal: Molecular & cellular proteomics : MCP
Published: May 13, 2026

Turning adaptive resistance into vulnerability: AUTAC-Mediated degradation of Mcl1.

Turning adaptive resistance into vulnerability: AUTAC-Mediated degradation of Mcl1.

Journal: Autophagy
Published: May 04, 2026
Showing 1-12 of 1,722

Last Updated: 09/26/2026